00_MJ_Intro_Budapest16.pptx

1078-1079 / 1173

ESTRO
2015
PROTON THERAPY: CLINICAL RESULTS
PRIMARY TUMOR
DRBE
Gy (RBE)
NUMBER
OF
PATIENTS
of patients
LOCAL CONTROL REFERENCE
Uveal melanoma 70 in 5 Fx
990
1922
99 % at 5 yr
96 % at 10 yr
Egger et al. (2001)
Gragoudas et al . (2002)
Skull base
chondrosarcoma
~ 69 202 95 % at 10 years
Liebsch, N., Personal
communication (2005)
Chordoma ~ 69 132 59 % / 44 % at 5 / 10 yr Terahara et al . (1999)
Prostate TIII - TIV
(photons ± proton boost)
67.2 vs. 75.6
(Phase III trial)
202 80 % vs. 92 % at 5 yr
60 % vs. 77 % at 8 yr
Shipley et al . (1995)
Prostate TIa - TII 74 1255
75 % / 73 % biochemical
disease-free survival
at 5 / 8 yr
Slater et al . (2004)
Prostate TI - TII
(photons ± proton boost)
70.2 vs. 79.2 393 61.4% vs. 80.4% at 5 yr Zietman et al . (2005)
Non-small cell lung
cancer. Stage I
73.8 27 86% at 2 yr Bush et al. (2004a)
Hepatic cancer
72 (16 Fx in 29 days)
63 (15 Fx in 3
weeks)
162
34
87 % at 5 yr
75% at 2 yr
Chiba et al . (2005)
Bush et al. (2004b)
Glioblastoma multiforme 90 BID in 5 weeks 23
34 % / 18 % survival
at 2 / 3 yr
Fitzek et al. (1999)
Adenocystic carcinoma of
the paranasal sinus
76  surgery 23 93% at 5 years Pommier et al . (2005)
Axial skeleton:
Chondrosarcoma
Chordoma
72.2
74.6
6
14
100% at 5 yr
53% at 5 yr
Hug et al . (1995)